167 related articles for article (PubMed ID: 12599228)
1. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Beer TM; Lemmon D; Lowe BA; Henner WD
Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
6. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
Woo TC; Choo R; Jamieson M; Chander S; Vieth R
Nutr Cancer; 2005; 51(1):32-6. PubMed ID: 15749627
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy.
Beer TM; Myrthue A; Garzotto M; O'hara MF; Chin R; Lowe BA; Montalto MA; Corless CL; Henner WD
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2225-32. PubMed ID: 15598784
[TBL] [Abstract][Full Text] [Related]
8. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
10. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of calcitriol and naproxen in recurrent prostate cancer.
Srinivas S; Feldman D
Anticancer Res; 2009 Sep; 29(9):3605-10. PubMed ID: 19667155
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
Chadha MK; Tian L; Mashtare T; Payne V; Silliman C; Levine E; Wong M; Johnson C; Trump DL
Cancer; 2010 May; 116(9):2132-9. PubMed ID: 20166215
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
14. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA;
J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
17. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
Cetnar JP; Malkowicz SB; Palmer SC; Wein AJ; Vaughn DJ
Urology; 2008 May; 71(5):942-6. PubMed ID: 18279928
[TBL] [Abstract][Full Text] [Related]
18. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
19. Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time.
Numata K; Azuma K; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2005 May; 35(5):256-9. PubMed ID: 15886268
[TBL] [Abstract][Full Text] [Related]
20. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.
Shalev M; Thompson TC; Frolov A; Lippman SM; Hong WK; Fritsche H; Kadmon D
Clin Cancer Res; 2000 Oct; 6(10):3845-9. PubMed ID: 11051228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
